NCT00019929View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

August 31, 2000

Study Completion Date

December 31, 2005

Conditions
Lung Cancer
Interventions
BIOLOGICAL

mutant p53 peptide pulsed dendritic cell vaccine

PROCEDURE

adjuvant therapy

Trial Locations (2)

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

37232-6838

Vanderbilt-Ingram Cancer Center, Nashville

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00019929 - Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter